Slide 1: Investor Webinar Presentation
Investor Webinar Presentation Melbourne, Australia, November 13, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday 14th November
Slide 2: About Immuron
About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com FORWARD-LOOKING ST
Slide 3: Watchlist Webinar Presentation
For personal use only WATCHLIST WEBINAR PRESENTATION 14 NOVEMBER, 2023 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1
Slide 4: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 5: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Financial Snapshot Major Shareholders Sh
Slide 6: Distribution Capability
DISTRIBUTION CAPABILITY Australia USA Canada ANB Canada Ontario, Canada Distributes to all For personal use only Retail Pharmacy provinces of Canada B2B Established E-commerce Developing Immuron Limited Vancouver, BC, Canada Key Commentary Australia • Retail network includes over 3,500 pharmacies RJ
Slide 7: Strong Sales Growth in Attractive Market
Traveller’s Diarrhoea (TD) STRONG SALES GROWTH Market is large and growing ~7% 3 CAGR IN AT TRACTIVE MARKET Industry tailwinds For personal use only Travel picking up significantly following COVID lockdowns Frequent 30% - 70% of travelers experience TD 4 Australia 12 months to July 2023 short term r
Slide 8: Technology Platform for Gut Mediated Diseases
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to m
Slide 9: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs Compound or Indication Phase Phase Phase Market For personal use only brand name I II III Traveler’s IMM-124E Diarrhea ETEC Travelan® challenge Clostridioides difficile IMM-529 Infection & Recurrence Our Partners’ Clinical Program
Slide 10: Valuable Sales Potential for Pipeline Products
VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the potential to address this u
Slide 11: Near Term Milestones Anticipated to Drive Value
NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 1H 2023 2H 2023 1H 2024 For personal use only • FDA IND1 approved for single • IRB Approval4 • 100% of patients enrolled • Topline results for IMM-124E daily dose IMM-124E ETEC2 • Initiated IMM-124E ETEC2 CHIM3 • Completion of In-patient phase
Slide 12: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 11
Slide 13: Scientific References
SCIENTIFIC REFERENCES For personal use only Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: volunteers 10.3109/00365521.2011.574726 Clinical Evaluation of